Michael Alexander Smith

CLO Michael Alexander Smith sold 6,149 shares of INSM at $108.47; stock now at $106.24, down 50.1% from 52-week high.

Michael Alexander Smith, Chief Legal Officer, sold 6,149 shares (reducing holdings from 47,762 to 41,613 shares) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, making this a scheduled, non-discretionary transaction. The sale occurred at $108.47 per share for total value of $666,982.03, while the company's current stock price stands at $106.24 within a 52-week range of $64.84–$212.75. INSMED remains unprofitable with net income of -$163,563,000.00 on quarterly revenue of $305,964,000.00, despite annual revenue growth of 66.7%. The broader context shows the stock has declined 50.1% from its 52-week high and 26.5% over the prior 30 days.

CLO Smith sold 19,638 shares at $150.98; stock now $163.52; prior INSM sales have been poorly timed, falling after 4 of 4 measurable recent trades.

Michael Alexander, Chief Legal Officer of INSMED Inc, sold 19,638 shares (27.5% of his pre-transaction holdings) at $150.98 on 2026-03-30 for $2,964,945.24. The stock now trades at $163.52, approximately 8.4% above the sale price, and is +9.5% over the past 30 days and -6.0% over 90 days. At the same-ticker level, Alexander's 5 prior INSM trades are a notable concern: all 4 measurable 30-day outcomes were negative (ranging from -4.1% to -14.4%), and his cross-ticker track record shows 20 prior sells with an average 90-day return of +11.7% (indicating most sells were followed by stock appreciation). However, against his broader pattern, his specific history at INSM has not generated well-timed outcomes to date. The company remains unprofitable with net income of $-370.0M offset by strong revenue growth of +66.7% year-over-year, suggesting fundamental execution risks. The sale comes as the stock trades -22.6% from its 52-week high, which combined with recent positive price momentum may reflect opportunistic timing by the insider, though the pattern of negative returns following his prior INSM sales warrants attention.

Chief Legal Officer Smith sells 24,774 shares at blended avg $155.77, reducing stake by 32.3%; stock now down 29.7% from 52-wk high.

Smith Michael Alexander, Chief Legal Officer, executed 3 separate sales totaling 24,774 shares for $3,859,157.05, reducing his holdings from 76,645 to 51,871 shares. The sales occurred at prices ranging from $153.93 to $156.53 on 2026-02-24, with a blended average price of $155.77. At the current price of $148.61, the stock has declined 7.0% in the past 30 days and 27.3% over 90 days, placing it down 29.7% from its 52-week high of $211.41. His prior 5 trades at INSM show a 90-day well-timed rate of 2 of 2 measurable outcomes (100%), though recent INSM sales from early January yielded negative 30-day returns of -12.9% to -14.4%. While his cross-ticker track record shows an 8.7% average 30-day return and a 52.94% 90-day well-timed rate across 20 prior sells, the company remains unprofitable (full-year net income of -$370.0M) despite strong revenue growth of 66.7% year-over-year, creating a fundamental tension between growth and profitability that warrants investor attention to outcomes following this large proportional sale.

CLO Michael Smith sold 3,158 shares at blended $174.00; stock now $170.27, -12.3% in 30d; unprofitable co with $36.3B market cap

Michael Alexander Smith, Chief Legal Officer of INSMED, executed 3 separate sales totaling 3,158 shares for $549,494.32 between January 6–8, 2026, at prices ranging from $173.33 to $175.07. The sales reduced his holdings by 5.2% to 57,037 shares. The stock has since declined to $170.27 (-19.5% from 52-week high, -12.3% in the last 30 days), a modest underperformance relative to the blended sale price of $174.00. Across his prior 5 sales at INSM (all on 2025-11-03), returns have been measurably positive at the 30-day horizon (ranging +10.0% to +14.2%), but his cross-ticker track record shows sells are rarely well-timed at the 90-day mark (25.00% well-timed rate), suggesting inconsistent predictive value. The company remains unprofitable ($-370.0M net income last fiscal year) despite 19.2% revenue growth, which creates structural uncertainty independent of near-term price action.

CLO Michael Alexander sold 27,130 shares at $181.01–$187.15 for $4,985,910.59; 30-day stock +18.1%, 90-day +71.0%.

Chief Legal Officer Michael Alexander executed 8 separate sales totaling 27,130 shares for $4,985,910.59 on 2025-11-03, reducing his holdings from 82,032 to 54,902 shares (a -33.1% reduction). The blended average sale price of $183.78 sits within the stock's 52-week range and 3.8% below the 52-week high of $194.22. Over the trailing 30 days the stock has risen 18.1%, and over 90 days it has risen 71.0%. Against his cross-ticker track record, Alexander has 14 prior sales with an average 90-day return of +27.6% and a 50.00% well-timed rate; at INSM specifically, his 5 prior sales (all on 2025-09-02) each showed positive 30-day returns (4.7%–8.2%), though 90-day outcomes remain unmeasurable. The company reported quarterly revenue of $142,342,000.00 with a full-year net loss of $-370,021,000.00, so this insider is selling while the company is unprofitable and the stock has rallied substantially post-sale.

CLO Smith sold 24.3K shares for $3.5M at $143.89 avg; reduces holdings 30.7% near 52-week high; stock up 27.7% in 30d, 93.6% in 90d

Smith Michael Alexander, Chief Legal Officer, executed 6 separate sales totaling 24,272 shares for $3,492,377.99 on 2025-09-02, reducing his holdings by 30.7% from 79,174 to 54,902 shares. The sales occurred at prices ranging from $141.16 to $145.89, with a blended average of $143.89, occurring within 1.9% of the 52-week high of $145.30. The stock has appreciated 27.7% over the preceding 30 days and 93.6% over 90 days. Across his same-ticker history at INSM, Smith's prior 5 trades show 3 of 5 were well-timed at the 90-day mark, though his cross-ticker track record (8 prior sells averaging 14.3% 30-day and 27.6% 90-day returns with 50% well-timed rate) offers limited predictive specificity here. INSM is a $30.1B market-cap company that generated $107.4M in quarterly revenue with a negative $321.7M net income most recently, reflecting unprofitability; annual revenue growth of 19.2% shows operational expansion despite losses. The size and price level of this sale relative to recent momentum warrants tracking of any subsequent company-specific developments.

CLO Smith sold 26,327 shares at blended avg $69.65 on 2025-05-30, reducing holdings by -27.0%

Smith Michael Alexander, Chief Legal Officer of INSM, executed two separate sales totaling 26,327 shares for $1,833,779.12, reducing his holdings by -27.0% from 97,372 to 71,045 shares. The transaction prices ($68.56 and $70.00) were near or above the current price of $73.08, within the 52-week range of $53.55–$83.83. His same-ticker sales history at INSM shows 4 of 5 prior sells were well-timed at the 90-day mark, with the most recent 2025-02-06 sale followed by 90-day decline of -15.6%. The company reported quarterly revenue of $92,823,000.00 but full-year net income of $-256,583,000.00, indicating sustained unprofitability despite +19.2% annual revenue growth. The substantial reduction in equity stake by a senior legal officer, combined with the insider's established pattern of well-timed sales at this ticker, warrants investor attention to execution quality and cash burn trajectory.

CLO Smith sells 20,650 shares of INSM at $80.90; -17.6% of holdings post-sale.

Smith Michael Alexander, Chief Legal Officer of INSMED Inc, sold 20,650 shares at $80.90 on 2025-02-06, reducing holdings from 117,260 to 96,610 shares (-17.6% of pre-transaction holdings). The sale occurred near the 52-week high of $81.44, with the stock up 21.6% over the prior 30 days and up 8.7% over 90 days. Within his same-ticker history at INSM, 3 of 5 prior sales showed negative 90-day returns, indicating a pattern of well-timed exits; this current sale's proximity to recent highs aligns with that pattern. However, the company remains unprofitable despite strong revenue growth of 24.4% annually, and Smith maintains substantial post-sale holdings of 96,610 shares, suggesting a partial rather than full exit from his position.

CLO Smith sells 27,871 shares at $74.35 avg for $2.1M, cuts holdings 29.1%, stock near 52-week highs

Michael Alexander, Chief Legal Officer at INSM, executed 2 separate sales totaling 27,871 shares for $2,072,223.36 on 2024-09-13, reducing his holdings by 29.1% from 95,727 to 67,856 shares. The blended average sale price of $74.35 represents a position 1.5% above the current price of $73.23 and sits 7.3% below the 52-week high of $79.01. The company remains unprofitable (net income $-300.6M in the latest full fiscal year), though revenue growth stands at 24.4% year-over-year. His same-ticker prior trade on 2024-05-28 delivered a positive 90-day return of 35.2%, which indicates that sale was poorly timed relative to subsequent share appreciation, and 0 of 1 prior measurable same-ticker sells were well-timed. This substantial reduction in equity stake warrants examination of whether the timing reflects valuation views or operational considerations at a company still operating at significant net losses.

CLO Michael Alexander sells 88,070 shares (49.8% of holdings) for $6.4M at blended $72.96 avg vs current $74.87

Smith Michael Alexander, Chief Legal Officer, executed 2 separate sales totaling 88,070 shares (88.1K shares) for $6,425,466.00 ($6.4M), reducing his stake from 176,797 shares to 88,727 shares post-transaction. The blended average price of $72.96 is below the current price of $74.87 but reflects actual market execution on 2024-08-12 when the stock was near its 52-week high of $77.98. INSM remains unprofitable (net income $-300,609,000.00 for the most recent full fiscal year) despite 24.4% annual revenue growth, and the stock has declined 3.4% in the 30 days since this filing and 4.0% from its 52-week peak. His prior open-market sell at this ticker (2024-05-28) showed a 30-day return of +35.2%, indicating that sale preceded further appreciation rather than a downturn.